Table 4.
Tumor response to electrochemotherapy according to surrogate definition of breast cancer intrinsic subtypes
| Response | Luminal A-like (n = 23), n (%) | Luminal B-like (HER2 negative) (n = 22), n (%) | Luminal B-like (HER2 positive) (n = 18), n (%) | Triple negative (n = 35), n (%) | HER2 positive (n = 11), n (%) |
|---|---|---|---|---|---|
| CR | 17 (73.9) | 11 (50.0) | 10 (55.6) | 20 (57.1) | 6 (54.5) |
| PR | 4 (17.4) | 9 (40.9) | 5 (27.8) | 11 (31.4) | 5 (45.5) |
| SD | 1 (4.3) | 2 (9.1) | 1 (5.6) | 4 (11.4) | 0 (0) |
| PD | 1 (4.3) | 0 (0) | 1 (5.6) | 0 (0) | 0 (0) |
| NA | 0 (0) | 0 (0) | 1 (5.6) | 0 (0) | 0 (0) |
According to Goldhirsh et al.11; n = 109 (in four patients, there was no reliable pathologic information). Luminal A-like tumors (ER and PgR positive, HER2 negative, Ki-67 low); luminal B-like, HER2-negative tumors (ER positive, HER2 negative, Ki-67 high and/or PgR low or negative); luminal B-like, HER2 positive tumors (ER positive, HER2 overexpressed or amplified); HER2 positive, nonluminal tumors (HER2 overexpressed or amplified, ER and PgR negative); triple negative tumors (ER, PgR, and HER2 negative)
CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not assessable, ER estrogen receptor, PR progesterone receptor